三维适形放疗联合TACE治疗肝癌并发门静脉癌栓疗效的Meta分析

doi:10.3969/j.issn.1672-5069.2015.02.009

摘要/Abstract

摘要： 目的应用荟萃（Meta）分析法探讨三维适形放疗(3-DCRT)联合TACE与单纯TACE治疗肝癌伴门脉癌栓的近期及远期疗效。方法按系统评价原则,对2000年~2014 年公开发表的有关3-DCRT 联合TACE与单纯TACE治疗肝癌伴门脉癌栓的临床随机对照研究进行系统评价。结果共有8篇文献纳入研究,累计3D-CRT联合TACE治疗463例,单纯TACE治疗386例,纳入研究存在异质性,采用随机效应模型分析。Meta分析显示：3D-CRT联合TACE组与单纯TACE组在有效率[OR 2.871,95%CI（1.426,5.783）]、控制率[OR 2.871,95%CI（1.426,5.783）]、1 a生存率[OR 2.993,95%CI（1.713,5.230）]、2 a生存率[OR 3.054,95%CI（1.170,7.973）]均存在统计学差异（P<0.05）。结论 3-DCRT 联合TACE 治疗肝癌伴门脉癌栓的近期及远期疗效优于单纯TACE 治疗,值得进一步验证。

关键词: 肝癌, 门脉癌栓, 放射治疗, 肝动脉化疗栓塞, Meta 分析

Abstract: Objective To analyze the short and long-term effects of three-dimensional conformal radiation therapy （3D-CRT） combined with TACE versus TACE alone for treatment of patients with hepatocellular carcinoma with portal vein tumor thrombus（PVTT）. Methods Retrieval was performed according to the principles of systemic assessment,then we conducted a meta-analysis to compare 3-DCRT combined with TACE versus TACE alone for treatment of patients with hepatocellular carcinoma with PVTT. Results A total of 8 randomized controlled trials were included,and 463 cases receiving 3-DCRT combined with TACE and 386 receiving TACE alone were recruited. Compared with in TACE alone,the 3D-CRT combined with TACE treatment had advantages in tumour therapeutic response [OR 2.871,95%CI（1.426,5.783）,P<0.05],control rate [OR 2.871,95%CI（1.426,5.783）,P<0.05],1-year survival [OR 2.993,95%CI（1.713,5.230）,P<0.05] and 2-year survival [OR 3.054,95%CI（1.170,7.973）,P<0.05]. Conclusion 3D-CRT combined with TACE is better than TACE alone in treatment of patients with hepatocellular carcinoma with PVTT,which warrants further study.

Key words: Hepatocellular carcinoma, Portal vein tumor thrombus, Radiation therapy, Transcatheter arterial chemoembolization, Meta-analysis

张立洁, 彭泉, 芦东徽, 侯宇宸, 付贵峰. 三维适形放疗联合TACE治疗肝癌并发门静脉癌栓疗效的Meta分析[J]. 实用肝脏病杂志, 2015, 18(3): 254-257.

Zhang Lijie, Peng Quan, Lu Donghui, et al.. Three-dimensional conformal radiation therapy combined with transcatheter arterial chemoembolization for treatment of patients with hepatocellular carcinoma with portal vein tumor thrombus: A meta-analysis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(3): 254-257.

参考文献

[1] Takayasu K. Transarterial chemoembolization for hepatocellular carcinoma over three decades:current progress and perspective. Jpn J Clin Oncol,2012,42（4）:247-255.
[2] Kim JH,Yoon HK,Kim SY,et al. Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis. Aliment Pharmacol Ther,2009,29（12）:1291-1298.
[3] Kothary N,Weintraub JL,Susman J,et al. Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk. J Vasc Interv Radiol,2007,18（12）:1517-1527.
[4] Yoon SM,Lim YS,Won HJ,et al. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein:long-term patient outcomes. Int J Radiat Oncol Biol Phys,2012,82（5）:2004-2011.
[5] Han K,Kim JH,Yoon HM,et al. Transcatheter arterial chemoembolization for infiltrative hepatocellular carcinoma:Clinical safety and efficacy and factors influencing patient survival. Korean J Radiol,2014,15（4）:464-471.
[6] 中国抗癌协会肝癌专业委员会.原发性肝癌诊断标准. 中华肝脏病杂志,2000,8（3）:135-138.
[7] Jadad AR,Moore RA,Carroll D,et al. Assessing the quality of reports of randomized clinical trials:is blinding necessary. Control Clin Trials,1996,17（1）:1-12.
[8] Lu DH,Fei ZL,Zhou JP,et al. A comparison between three-dimensional conformal radiotherapy combined with interventional treatment and interventional treatment alone for hepatocellular carcinoma with portal vein tumour thrombosis. J Med Imaging Radiat Oncol,2015,59（1）:109-114.
[9] 夏兴洲. 马颖光. 刘伟. 肝动脉栓塞化疗序贯三维适形放疗治疗肝癌合并门脉癌栓. 中华肝脏病杂志,2007,15（3）:236-237.
[10] 徐爱兵,苏小琴,彭春雷,等. 肝动脉化疗栓塞联合三维适形放疗治疗肝癌合并门脉癌栓的临床对照研究. 胃肠病学和肝病学杂志,2007,16（4）:323-325.
[11] 李吉燮,吕胜吉,廉东延,等. 肝动脉化疗栓塞联合三维适形放疗治疗原发性肝癌合并门静脉瘤栓的临床对照研究. 中国医药导报,2009,6（19）:27-29.
[12] 吴志军,蔡晶,徐爱兵,等. 三维适形放疗联合肝动脉化疗栓塞治疗肝癌伴门脉癌栓的临床观察.中华医学杂志,2011,91（40）:2841-2844.
[13] 张孔志,余文,陈示光,等. TACE联合放疗对原发性肝癌合并门静脉癌栓患者生存的影响. 中国肿瘤临床,2012,39（1）:35-37.
[14] 刘兴安,张松,单国用,等.肝动脉化疗栓塞联合三维适形放射治疗对肝癌合并门静脉癌栓近期疗效. 临床荟萃,2012,27（3）:189-192.
[15] 刘永国.T ACE联合三维适形放疗治疗肝癌合并门静脉癌栓的疗效观察. 四川医学,2012,33（5）:790-792.
[16] Block TM,Mehta AS,Fimmel CJ,et al. Molecular viral oncology of hepatocellular carcinoma. Oncogene,2003,22（33）:5093-5107.
[17] 中国抗癌协会肝癌专业委员会,中国抗癌协会临床肿瘤学协作专业委员会,中华医学会肝病学分会肝癌学组. 原发性肝癌规范化诊治的专家共识.临床肝胆病杂志,2009,25（2）：83-92.
[18] Nishikawa H,Inuzuka T,Takeda H.A case of advanced hepatocellular carcinoma with portal vein tumor thrombus refractory to epirubicin that showed marked decrease in tumor markers after transcatheter arterial infusion with miriplatin. Case Rep Oncol,2011,4（2）:327-335.
[19] Cabibbo G,Enea M,Attanasio M,et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma.Hepatology,2010,51（4）:1274-1283.
[20] Hashimoto Y,Wada H,Kobayashi S. A long-term survival case of hepatocellular carcinoma with portal vein and inferior vena cava tumor thrombi. Gan To Kagaku Ryoho,2010,37（12）:2693-2695.
[21] Molinari M,Kachura JR,Dixon E,et al. Transarterial chemoembolisation for advanced hepatocellular carcinoma：results from a North American cancer certre. Clin Oncol（R Coll Radiol）,2006,18（9）:6846-6892.
[22] Park HC,Seong J,Han KH,et a1. Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys,2002,54（1）：150-155.
[23] 谭新劲,任丽,刘晋湘,等.TACE 联合三维适形放疗治疗中晚期原发性肝癌疗效观察. 实用肝脏病杂志,2011,14（6）:433-435.
[24] Lo SS,Dawsom LA,Kim EY,et al. Stereotactic body radiation therapy for hepatocellular carcinoma. Discov Med,2010,9（48）:404-410.
[25] Sawrie SM,Fiveash JB,Caudell JJ. Stereotactic body radiation therapy for liver metastases and primary hepatocellular carcinoma:normal tissue tolerances and toxicity. Cancer Control,2010,17（2）:111-119.
[26] 蒋富强,康静波. 原发性肝癌伴门静脉癌栓治疗进展. 实用肝脏病杂志,2013,16（3）:286-288.
[27] You CR,Jang JW,Kang SH,et a1. Efficacy of transarterial chemolipiodolization with or without 3-dimensional conformal radiotherapy for huge HCC with portal vein tumor thrombosis. Korean J Hepatol,2007,13（3）:378-386.